Francis Decroos, MD
Retina Specialist · Hixson, TNNPI 1871627554
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $368 of the $602 with a category attached, or 61.1%. Novartis accounts for 87.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $516 and has fallen 95.2% since, to $25 in 2024. That places this record below the midpoint for retina specialist clinicians in TN, where the typical reported total is $3,018.
Across 10 payments — averaging $60.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$529
- Alcon$41
- Coherus Oncology, Inc.$32
Across 24 payments — averaging $4187.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$62K
- Roche TCRC, Inc.$25K
- Novo Nordisk AS$13K
- Novartis$1K
What the payments were for
- Travel & lodging$23439%
- Food & beverage$36861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $529 |
| Alcon | 2 | $41 |
| Coherus Oncology, Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEOVU$462
How this compares
$602 in reported general payments places this provider in the 5th percentile of 58 retina specialist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 39 | $7,995 |
| Prednisolone Acetate | 127 | $6,835 |
| Brimonidine Tartrate | 36 | $2,536 |
| Loteprednol Etabonate | 12 | $2,371 |
| Atropine Sulfate | 37 | $1,410 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 87 | $1,289 |
| Ketorolac Tromethamine | 43 | $1,133 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 36 | $251 |
| Timolol Maleate | 15 | $70 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Hixson
- Devon GhodasraHixson$640
- Asghar HaiderHixson$607
- Rohan ShahHixson$575
- Richard BreazealeHixson$33
- Steve CharlesGermantown$5.8M
- Carl AwhNashville$1.3M
- Peter SonkinNashville$949K
- Brandon BusbeeNashville$566K
- Eric SchneiderNashville$134K
- David ReichsteinNashville$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.